Akari Therapeutics to Present at the 2026 Biotech Showcase

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing [3] - The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors with minimal off-target effects [3] - AKTX-101 has shown significant activity and prolonged survival in preclinical studies compared to traditional ADCs, and it has the potential to be synergistic with checkpoint inhibitors [3] Strategic Priorities - Akari Therapeutics aims to initiate IND enabling studies for AKTX-101, with a goal of starting its First-In-Human trial by late 2026 or early 2027 [3] - The company is also advancing AKTX-102, an ADC targeting a novel antigen relevant in gastrointestinal and lung cancers [3] Upcoming Presentation - Abizer Gaslightwala, President and CEO of Akari Therapeutics, will present at the 2026 Biotech Showcase on January 13, 2026, at 9:30 AM PST [1][2] - The presentation will cover an overview of Akari's ADC platform, strategic priorities, and key milestones for 2026 [1]